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CONCLUSIONS
In conclusion, the UHPLC-MS method with ultrafiltra-
tion described in this study demonstrated a good capability
for determining unbound VPA concentrations. The method
has advantages of easy sample preparation and rapid analysis,
and it can be used to facilitate large-scale investigations of the
relationship between unbound VPA concentrations and
clinical outcomes in epileptic children.
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ERRATUM
Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual
Variability of Tacrolimus Concentrations Early After Kidney Transplant: Erratum
In the August 2016 issue of Therapeutic Drug Monitoring in the article “Prospective Randomized Trial Investigating the
Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early After Kidney
Transplant”, the author Juliana F. Mansur should be listed as Juliana B. Mansur.
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